GSK plc
bepirovirsen
chronic hepatitis B
Date
TBD
Advisory committee · Date TBD estimated
What's at stake
An FDA advisory committee reviews bepirovirsen for chronic hepatitis B around Date TBD. The panel's public vote often front-runs the agency's final verdict — and the share price.
Primary source
· SEC 6-K
verified 12h ago
“Bepirovirsen demonstrated a statistically significant and clinically meaningful functional cure rate.”